+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2020

  • ID: 4986889
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 83 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Acea Biotech Inc
  • Ascil Proyectos SL
  • DermBiont Inc
  • Hexima Ltd
  • Moberg Pharma AB
  • Novabiotics Ltd
  • MORE
Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2020, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape.

Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 7, 3, 4, 1 and 2 respectively.

Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Acea Biotech Inc
  • Ascil Proyectos SL
  • DermBiont Inc
  • Hexima Ltd
  • Moberg Pharma AB
  • Novabiotics Ltd
  • MORE
  • Introduction
  • Report Coverage
  • Onychomycosis (Tinea Unguium) - Overview
  • Onychomycosis (Tinea Unguium) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Onychomycosis (Tinea Unguium) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development
  • Acea Biotech Inc
  • Almirall SA
  • Ascil Proyectos SL
  • Blueberry Therapeutics Ltd
  • CSA Biotechnologies LLC
  • DermBiont Inc
  • Exodos Life Sciences Limited Partnership
  • Hallux Inc
  • Hexima Ltd
  • Kaken Pharmaceutical Co Ltd
  • Meiji Seika Pharma Co Ltd
  • Moberg Pharma AB
  • Mycovia Pharmaceuticals Inc
  • NAL Pharmaceuticals Ltd
  • Novabiotics Ltd
  • Novan Inc
  • Photonamic GmbH & Co KG
  • Sanotize Research And Development Corp
  • Onychomycosis (Tinea Unguium) - Drug Profiles
  • aminolevulinic acid hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Onychomycosis (Tinea Unguium) - Dormant Projects
  • Onychomycosis (Tinea Unguium) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
List of Tables
  • Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by Acea Biotech Inc, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by Almirall SA, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by Ascil Proyectos SL, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by CSA Biotechnologies LLC, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by DermBiont Inc, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by Exodos Life Sciences Limited Partnership, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by Hallux Inc, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by Hexima Ltd, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by Mycovia Pharmaceuticals Inc, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by Novan Inc, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by Photonamic GmbH & Co KG, H1 2020
  • Onychomycosis (Tinea Unguium) - Pipeline by Sanotize Research And Development Corp, H1 2020
  • Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2020
  • Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2020 (Contd..1), H1 2020
List of Figures
  • Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Acea Biotech Inc
  • Almirall SA
  • Ascil Proyectos SL
  • Blueberry Therapeutics Ltd
  • CSA Biotechnologies LLC
  • DermBiont Inc
  • Exodos Life Sciences Limited Partnership
  • Hallux Inc
  • Hexima Ltd
  • Kaken Pharmaceutical Co Ltd
  • Meiji Seika Pharma Co Ltd
  • Moberg Pharma AB
  • Mycovia Pharmaceuticals Inc
  • NAL Pharmaceuticals Ltd
  • Novabiotics Ltd
  • Novan Inc
  • Photonamic GmbH & Co KG
  • Sanotize Research And Development Corp
Note: Product cover images may vary from those shown
Adroll
adroll